X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2125) 2125
Publication (108) 108
Book Review (70) 70
Magazine Article (29) 29
Newsletter (29) 29
Newspaper Article (28) 28
Book Chapter (7) 7
Conference Proceeding (3) 3
Data Set (3) 3
Trade Publication Article (3) 3
Paper (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1737) 1737
multiple sclerosis (1354) 1354
interferon-beta - therapeutic use (1033) 1033
interferon beta-1b (951) 951
clinical neurology (873) 873
female (841) 841
index medicus (787) 787
adult (780) 780
multiple sclerosis - drug therapy (779) 779
male (778) 778
interferon beta-1a (655) 655
middle aged (540) 540
double-blind (524) 524
interferon (507) 507
neurosciences (497) 497
adjuvants, immunologic - therapeutic use (446) 446
glatiramer acetate (436) 436
multiple sclerosis, relapsing-remitting - drug therapy (426) 426
treatment outcome (415) 415
neurology (405) 405
interferon beta (374) 374
magnetic resonance imaging (345) 345
placebo-controlled trial (321) 321
disease progression (290) 290
interferon-beta (271) 271
care and treatment (266) 266
immunologic factors - therapeutic use (258) 258
multicenter (258) 258
drug therapy (255) 255
therapy (253) 253
disability (245) 245
research (240) 240
multiple sclerosis - immunology (239) 239
immunosuppressive agents - therapeutic use (237) 237
medicine & public health (235) 235
pharmacology & pharmacy (220) 220
multiple sclerosis - therapy (216) 216
peptides - therapeutic use (214) 214
interferon-beta - adverse effects (209) 209
biological response modifiers (207) 207
immunology (206) 206
recurrence (195) 195
interferon-beta - administration & dosage (192) 192
adolescent (187) 187
neutralizing antibodies (186) 186
disability evaluation (185) 185
time factors (181) 181
health aspects (165) 165
patients (163) 163
interferon-beta - immunology (161) 161
multiple sclerosis - diagnosis (153) 153
clinical trials as topic (151) 151
clinical trials (149) 149
psychiatry (148) 148
disease (146) 146
follow-up studies (145) 145
multiple-sclerosis (144) 144
young adult (144) 144
animals (142) 142
multiple sclerosis - pathology (142) 142
brain - pathology (137) 137
multiple sclerosis - physiopathology (137) 137
mri (135) 135
natalizumab (134) 134
recombinant proteins - therapeutic use (131) 131
medicine, general & internal (129) 129
aged (126) 126
medicine (126) 126
diagnostic-criteria (124) 124
research article (119) 119
neuroradiology (117) 117
retrospective studies (115) 115
analysis (114) 114
studies (110) 110
dosage and administration (109) 109
multiple sclerosis, relapsing-remitting - immunology (109) 109
interferon-beta - pharmacology (108) 108
follow-up (107) 107
prospective studies (107) 107
efficacy (106) 106
antibodies (105) 105
ifn-beta (104) 104
natural-history (103) 103
risk factors (103) 103
development and progression (100) 100
usage (100) 100
adjuvants, immunologic - administration & dosage (98) 98
cytokines (98) 98
experimental autoimmune encephalomyelitis (98) 98
secondary progressive ms (96) 96
drug administration schedule (95) 95
multiple sclerosis, chronic progressive - drug therapy (95) 95
adjuvants, immunologic - adverse effects (94) 94
diagnosis (94) 94
trial (91) 91
dose-response relationship, drug (89) 89
medical research (87) 87
quality of life (87) 87
randomized controlled trials as topic (87) 87
quality-of-life (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2104) 2104
German (30) 30
Russian (25) 25
Spanish (21) 21
French (19) 19
Japanese (7) 7
Polish (7) 7
Hungarian (5) 5
Croatian (3) 3
Dutch (3) 3
Chinese (1) 1
Czech (1) 1
Danish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Neurology, ISSN 0340-5354, 12/2017, Volume 264, Issue 12, pp. 2436 - 2449
Cognitive impairment (CI) affects 40–65% of multiple sclerosis (MS) patients. This study attempted evaluating the effects of fingolimod and interferon beta-1b... 
Neurology | Neurosciences | Interferon beta-1b | Medicine & Public Health | Fingolimod | Brief repeatable battery test | Brain atrophy | Delis–Kaplan executive function test | Neuroradiology | Cognitive impairment | ORAL FINGOLIMOD | NATALIZUMAB | CLINICAL NEUROLOGY | IMPAIRMENT | DECLINE | EXECUTIVE FUNCTION SYSTEM | Delis-Kaplan executive function test | PLACEBO-CONTROLLED TRIAL | DYSFUNCTION | VALIDITY | Cognition Disorders - diagnostic imaging | Humans | Middle Aged | Male | Depression - etiology | Young Adult | Depression - drug therapy | Cognition Disorders - etiology | Statistics, Nonparametric | Electrocardiography | Adult | Female | Fingolimod Hydrochloride - therapeutic use | Multiple Sclerosis, Relapsing-Remitting - complications | Disability Evaluation | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Treatment Outcome | Cognition Disorders - drug therapy | Neuropsychological Tests | Magnetic Resonance Imaging | Pilot Projects | Interferon beta-1b - therapeutic use | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Adolescent | Longitudinal Studies | Executive Function - drug effects | Immunologic Factors - therapeutic use | Complications and side effects | Usage | Multiple sclerosis | Care and treatment | Magnetic resonance imaging | Patient outcomes | Dosage and administration | Neuroimaging | Executive function | Nuclear magnetic resonance--NMR | Cognitive ability | Gadolinium | Interferon | Clinical outcomes | Original Communication
Journal Article
Climacteric, ISSN 1369-7137, 11/2016, Volume 19, Issue 6, pp. 599 - 600
Journal Article
by Fitzgerald, Kathryn C and Munger, Kassandra L and Hartung, Hans‐Peter and Freedman, Mark S and Montalbán, Xavier and Edan, Gilles and Wicklein, Eva‐Maria and Radue, Ernst‐Wilhelm and Kappos, Ludwig and Pohl, Christoph and Ascherio, Alberto and Strasser‐Fuchs, S and Berger, T and Vass, K and Sindic, C and Dubois, B and Dive, D and Debruyne, J and Metz, L and Rice, G and Duquette, P and Lapierre, Y and Freedman, M and Traboulsee, A and O'Connor, P and Štourač, P and Talab, R and Zapletalova, O and Kovařova, I and Medova, E and Fiedler, J and Frederiksen, J and Brochet, B and Moreau, T and Vermersch, P and Pelletier, J and Edan, G and Clanet, M and Clavelou, P and Lebrun‐Frenay, C and Gout, O and Kallela, M and Pirttila, T and Ruutiainen, J and Koivisto, K and Reunanen, M and Elovaara, I and Villringer, A and Altenkirch, H and Wessel, K and Hartung, H‐P and Steinke, W and Kölmel, H and Oschmann, P and Diem, R and Dressel, A and Hoffmann, F and Baum, K and Jung, S and Petereit, H and Reske, D and Sailer, M and Kohler, J and Sommer, N and Hohlfeld, R and Henn, K‐H and Tumani, H and Gold, R and Rieckmann, P and Komoly, R and Gacs, G and Jakab, G and Csiba, L and Vecsei, L and Miller, A and Karussis, D and Chapman, J and Ghezzi, A and Comi, G and Gallo, P and Cosi, V and Durelli, L and Anten, B and Visser, L and Myhr, K‐M and Szczudlik, A and Selmaj, K and Stelmasiak, Z and Podemski, R and Maciejek, Z and Cunha, L and Sega‐Jazbec, S and Montalban, X and Arbizu, T and Saiz, A and Barcena, J and Arroyo, R and Fernandez, O and Izquierdo, G and Casanova, B and ... and BENEFIT Study Grp and BENEFIT Study Group
Annals of Neurology, ISSN 0364-5134, 07/2017, Volume 82, Issue 1, pp. 20 - 29
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2014, Volume 9, Issue 11, p. e113933
Journal Article
Applied Microbiology and Biotechnology, ISSN 0175-7598, 3/2017, Volume 101, Issue 5, pp. 1975 - 1987
Journal Article
Multiple Sclerosis, ISSN 1352-4585, 04/2016, Volume 22, Issue 4, pp. 533 - 543
Journal Article
Journal Article
by Arabi, Yaseen M and Alothman, Adel and Balkhy, Hanan H and Al-Dawood, Abdulaziz and AlJohani, Sameera and Al Harbi, Shmeylan and Kojan, Suleiman and Al Jeraisy, Majed and Deeb, Ahmad M and Assiri, Abdullah M and Al-Hameed, Fahad and AlSaedi, Asim and Mandourah, Yasser and Almekhlafi, Ghaleb A and Sherbeeni, Nisreen Murad and Elzein, Fatehi Elnour and Memon, Javed and Taha, Yusri and Almotairi, Abdullah and Maghrabi, Khalid A and Qushmaq, Ismael and Al Bshabshe, Ali and Kharaba, Ayman and Shalhoub, Sarah and Jose, Jesna and Fowler, Robert A and Hayden, Frederick G and Hussein, Mohamed A and Martin, Greg S and Schoenfeld, David A and Walmsley, Sharon L and Carson, Shannon and Harbi, Shmeylan Al and Jeraisy, Majed Al and Muhaidib, Mohammed Al and Musharaf, Sadat and Anizi, Hala Al and Dael, Reggie and AlMazroa, Mohammad and Asiri, Ayed and Memish, Ziad A and Ghazal, Sameeh S and Alfaraj, Sarah H and Harthy, Abdulrahman Al and Sulaiman, Mohammed Al and Mady, Ahmed and Ahmad, Abdulrauf and Ghaleb A Almekhlafi, A Almekhlafi and Muhammed, Reema and Samirrai, Shatha Al and Awad, Shatha and Cabal, Rylen Cabio and Onazi, Bander Al and Aljuhani, Maha and Vince, Melven and Enani, Mushira Al and Alqurashi, Alaa and Alenezi, Fatimah and Alkhani, Nada and Thaqafi, Abdulhakeem and Oraabi, Ohoud Al and Rifai, Jalal and Elsamadisi, Pansy and Medhat, S.Hendy and Basher, Sara AbuBaker and Abduldhaher, Muhammed and Bajhamoum, Wael and Alahsa, Sarah Shalhoub and Bashir, Shahinaz and Al-Dossary, Ibraheem and Al-Muhainy Dammam, Bader and Khobar, Shehab Suliman Al and Alshahrani, Mohammed S and Al Jabri, Ahmad and Farid, Magdy and Alaidarous, Alawi and Alseraihi, Wael and Shahada, Husam and Taif, Jinish Shimi and And the MIRACLE trial group
Trials, ISSN 1745-6215, 01/2018, Volume 19, Issue 1, pp. 81 - 13
Journal Article